Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
The new single-tablet NNRTI regimen was less likely than Atripla to cause neurological symptoms.
Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.